Combined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, Preventing their exhaustion

Cancer Science

Volumn 107, Issue 4, 2016, Pages 398-406

  Kano, Yosuke ^a   Iguchi, Takahiro ^a   Matsui, Hiroto ^a   Adachi, Keishi ^a   Sakoda, Yukimi ^a   Miyakawa, Tomoya ^b   Doi, Shun ^b   Hazama, Shoichi ^a   Nagano, Hiroaki ^a   Ueyama, Yoshiya ^a   Tamada, Koji ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NEC CORPORATION   (Japan)

Author keywords

Adjuvants; Cancer vaccine; LAG 3; Poly(I:C); T cell exhaustion

Indexed keywords

CANCER VACCINE; FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT; LAG 3 IG; P1A PEPTIDE VACCINE; PEPTIDE VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; CD223 ANTIGEN; IMMUNOGLOBULIN G; LEUKOCYTE ANTIGEN;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER FATIGUE; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SURVIVAL; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GENE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE ACTIVATION GENE 3; MASTOCYTOMA; MOUSE; MOUSE MODEL; NONHUMAN; P815 CELL LINE; PRIORITY JOURNAL; TH1 CELL; TUMOR REJECTION; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CD8+ T LYMPHOCYTE; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; POLY I-C;

EID: 84963686212     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12861     Document Type: Article

References (45)

1. Aranda F, Vacchelli E, Eggermont A et al. Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology 2013; 2: e26621.
2. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24: 175-208.
3. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014; 14: 135-46.
4. Pol J, Bloy N, Buque A et al. Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology 2015; 4(4): e974411.
5. Banday AH, Jeelani S, Hruby VJ. Cancer vaccine adjuvants-recent clinical progress and future perspectives. Immunopharmacol Immunotoxicol 2015; 37(1): 1-11.
6. Kissick HT, Sanda MG. The role of active vaccination in cancer immunotherapy: lessons from clinical trials. Curr Opin Immunol 2015; 35: 15-22.
7. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-15.
8. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22.
9. Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 2010; 22(2): 223-30.
10. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006; 90: 51-81.
11. Ammi R, De Waele J, Willemen Y et al. Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. Pharmacol Ther 2015; 146: 120-31.
12. Longhi MP, Trumpfheller C, Idoyaga J et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 2009; 206: 1589-602.
13. Triebel F. LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol 2003; 24: 619-22.
14. Andreae S, Piras F, Burdin N, Triebel F. Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223). J Immunol 2002; 168: 3874-80.
15. El Mir S, Triebel F. A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens. J Immunol 2000; 164: 5583-9.
16. Okada H, Kalinski P, Ueda R et al. Induction of CD8 + T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with -type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011; 29: 330-6.
17. Sabbatini P, Tsuji T, Ferran L et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 2012; 18: 6497-508.
18. Romano E, Michielin O, Voelter V et al. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J Transl Med 2014; 12: 97.
19. Wang-Gillam A, Plambeck-Suess S, Goedegebuure P et al. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest New Drugs 2013; 31: 707-13.
20. Brignone C, Gutierrez M, Mefti F et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 2010; 8: 71.
21. Brignone C, Escudier B, Grygar C, Marcu M, Triebel F. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 2009; 15: 6225-31.
22. Sarma S, Guo Y, Guilloux Y, Lee C, Bai XF, Liu Y. Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo. J Exp Med 1999; 189: 811-20.
23. Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 1991; 173: 1373-84.
24. Grohmann U, Bianchi R, Fioretti MC et al. CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide. Eur J Immunol 1995; 25: 2797-802.
25. Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol 2013; 25(2): 214-21.
26. Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol 2015; 36: 265-76.
27. Han X, Ye P, Luo L et al. The development and functions of CD4(+) T cells expressing a transgenic TCR specific for an MHC-I-restricted tumor antigenic epitope. Cell Mol Immunol 2011; 8: 333-40.
28. Benwell RK, Hruska JE, Fritsche KL, Lee DR. Double stranded RNA- relative to other TLR ligand-activated dendritic cells induce extremely polarized human Th1 responses. Cell Immunol 2010; 264(2): 119-26.
29. Verdijk RM, Mutis T, Esendam B et al. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol 1999; 163(1): 57-61.
30. Smits EL, Ponsaerts P, Van de Velde AL et al. Proinflammatory response of human leukemic cells to dsRNA transfection linked to activation of dendritic cells. Leukemia 2007; 21: 1691-9.
31. Datta SK, Redecke V, Prilliman KR et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 2003; 170: 4102-10.
32. Durand V, Wong SY, Tough DF, Le Bon A. IFN-alpha/beta-dependent cross-priming induced by specific toll-like receptor agonists. Vaccine 2006; 24(Suppl 2): S2-22-3.
33. Lauzon NM, Mian F, MacKenzie R, Ashkar AA. The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell Immunol 2006; 241(2): 102-12.
34. Cheng YS, Xu F. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther 2010; 10: 1219-23.
35. Huard B, Prigent P, Tournier M, Bruniquel D, Triebel F. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol 1995; 25: 2718-21.
36. Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol 2015; 42: 587-600.
37. Nagato T, Lee YR, Harabuchi Y, Celis E. Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. Clin Cancer Res 2014; 20: 1223-34.
38. Pulko V, Liu X, Krco CJ et al. TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J Immunol 2009; 183: 3634-41.
39. Woo SR, Turnis ME, Goldberg MV et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012; 72: 917-27.
40. Smyth K, Garcia K, Sun Z, Tuo W, Xiao Z. TLR agonists are highly effective at eliciting functional memory CTLs of effector memory phenotype in peptide immunization. Int Immunopharmacol 2013; 15(1): 67-72.
41. Qiu F, Cui Z. CD4 + T helper cell response is required for memory in CD8 + T lymphocytes induced by a poly(I:C)-adjuvanted MHC I-restricted peptide epitope. J Immunother 2007; 30(2): 180-9.
42. Workman CJ, Cauley LS, Kim IJ, Blackman MA, Woodland DL, Vignali DA. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol 2004; 172: 5450-5.
43. Huang CT, Workman CJ, Flies D et al. Role of LAG-3 in regulatory T cells. Immunity 2004; 21: 503-13.
44. Kimura T, McKolanis JR, Dzubinski LA et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 2013; 6(1): 18-26.
45. Hailemichael Y, Dai Z, Jaffarzad N et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med 2013; 19: 465-72.